Epoetin beta
Also known as: EPO-beta, Epoetin beta, Epoetinum beta, NeoRecormon, Recormon, rhEPO, rHuEPO-beta
Source Epoetin beta at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Epoetin beta (brand NeoRecormon) is a recombinant human erythropoietin used to treat anemia associated with chronic kidney disease, chemotherapy, and HIV infection by stimulating red blood cell production.
Mechanism of Action
Binds erythropoietin receptors on erythroid progenitor cells, stimulating proliferation, differentiation, and survival of red blood cell precursors, thereby increasing red blood cell mass.
Routes of Administration
Goals & Uses
- Treatment of anemia in chronic kidney diseaseHematology / NephrologyHigh
- Improvement of quality of lifePatient Reported OutcomesModerate
- Anemia in premature neonatesNeonatologyModerate
- Reduction of allogeneic blood transfusionsPerioperative MedicineModerate
- Anemia associated with myelodysplastic syndromesHematology / OncologyModerate
- Correction of anemiaHematologyHigh
- Chemotherapy-induced anemiaOncology / HematologyHigh
Contraindications
- Thrombotic risk or recent thrombotic eventCardiovascular / HematologicalModerate
- Cancer patients with curative intent receiving chemotherapyOncologyHigh
- Hypersensitivity to epoetin beta or excipientsAllergic / ImmunologicalHigh
- Active malignancy receiving chemotherapyOncologyModerate
- Known hypersensitivity to epoetin beta or any excipientsAllergyHigh
- Uncontrolled hypertensionCardiovascularHigh
- Pure red cell aplasia (PRCA) due to prior ESA therapyImmunologicalHigh
Adverse Effects
- Flu-like symptomsSystemic/ImmunologicalUncommon
- HypertensionCardiovascularCommonHigh blood pressure
- Injection site reactionsLocalCommon
- HeadacheNeurologicCommonPain in the head or upper neck
- Thromboembolic eventsCardiovascularRare
- SeizuresNeurologicalRare
- Pure red cell aplasia (PRCA)Immunological / HematologicalRare
- Thrombotic/thromboembolic eventsCardiovascular / HematologicalUncommon
Drug Interactions
- Antihypertensive agentsModerate
- CyclosporineModerate
- Iron deficiencyModerate
- Iron supplementsModerate
- ACE inhibitorsLow
- ACE inhibitors / Angiotensin receptor blockersLow
Population Constraints
- PregnancyReproductive SafetyRelative
- Patients with hemoglobin >10 g/dL at initiationHematologicalRelative
- Pediatric patientsAgeRelative
- LactationReproductiveRelative
- Pregnant or breastfeeding womenReproductiveRelative
- Cancer patients not receiving chemotherapyOncologicalRelative
Regulatory Status
- European UnionApprovedApproved: anemia due to chronic kidney disease, anemia secondary to chemotherapy, anemia in HIV infectionMarketed as NeoRecormon.
- United StatesUnapprovedEpoetin alfa is the FDA‑approved product; epoetin beta not submitted.
- United KingdomApprovedApproved: CKD‑related anemia, chemotherapy‑induced anemiaAligned with EU approval.
Approved in the European Union and several other jurisdictions; not approved in the United States where epoetin alfa is the marketed product.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Epoetin beta?
Epoetin beta (brand NeoRecormon) is a recombinant human erythropoietin used to treat anemia associated with chronic kidney disease, chemotherapy, and HIV infection by stimulating red blood cell production.
What is Epoetin beta used for?
Epoetin beta is educationally associated with: Treatment of anemia in chronic kidney disease, Improvement of quality of life, Anemia in premature neonates, Reduction of allogeneic blood transfusions, Anemia associated with myelodysplastic syndromes, Correction of anemia, Chemotherapy-induced anemia. Educational only — not medical advice.
How is Epoetin beta administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Epoetin beta?
Reported adverse effects include: Flu-like symptoms, Hypertension, Injection site reactions, Headache, Thromboembolic events, Seizures, Pure red cell aplasia (PRCA), Thrombotic/thromboembolic events. This list is not exhaustive — consult a qualified clinician.
Who should avoid Epoetin beta?
Recorded contraindications: Thrombotic risk or recent thrombotic event, Cancer patients with curative intent receiving chemotherapy, Hypersensitivity to epoetin beta or excipients, Active malignancy receiving chemotherapy, Known hypersensitivity to epoetin beta or any excipients, Uncontrolled hypertension, Pure red cell aplasia (PRCA) due to prior ESA therapy. Consult a qualified clinician before use.